What’s the current market cap for AstraZeneca stock?

AstraZeneca (AZN) has a market cap of $278bn as of June 18, 2026.

What is the P/E ratio for AstraZeneca stock?

The price to earnings (P/E) ratio for AstraZeneca (AZN) stock is 26.79 as of June 18, 2026.

Does AstraZeneca stock pay dividends?

Yes, the AstraZeneca (AZN) stock pays dividends to shareholders. As of June 18, 2026, the dividend rate is $3.2 and the yield is 2.44%. AstraZeneca has a payout ratio of 46.07% on a trailing twelve-month basis.

When is the next AstraZeneca dividend payment date?

The next AstraZeneca (AZN) dividend payment date is unconfirmed.

What is the beta indicator for AstraZeneca?

AstraZeneca (AZN) has a beta rating of 0.22. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy AstraZeneca stock | $AZN Share Price

About AstraZeneca

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Ticker

$AZN

Sector

Health

Primary listing

NYSE

Employees

96,100

Headquarters

Cambridge, United Kingdom

Website

www.astrazeneca.com

AstraZeneca Metrics

BasicAdvanced

$278bn

26.79

$6.64

0.22

$3.20

2.44%

Bulls say / Bears say

The FDA approval of the hypertension pill Baxfendy positions AstraZeneca to capture over $5 billion in annual sales, diversifying its portfolio beyond oncology and bolstering revenue growth (Bloomberg)

Its upgrade to a full listing on the New York Stock Exchange has broadened access to U.S. investors, improved liquidity, and underpinned share support as evidenced by the $187.50 opening price on launch day (Bloomberg)

A £300 million investment in UK life sciences infrastructure, including new R&D and manufacturing facilities at Cambridge and Macclesfield, enhances capacity for innovation and production resilience (Bloomberg)

An FDA advisory panel’s rejection of its experimental breast cancer drug in April 2026 underscores challenges in advancing key oncology assets, posing a setback to AstraZeneca’s growth projections in its highest‐margin segment (Bloomberg)

Plans to launch low‐cost obesity medications amid market pressure risk compressing margins relative to existing therapies, potentially diluting profitability in an increasingly competitive weight‐loss sector (Bloomberg)

AstraZeneca’s commitment to invest $15 billion in China through 2030 entails substantial capital outlay in a complex regulatory environment, which may strain free cash flow and defer returns on investment (Bloomberg)

Data summarised monthly by Lightyear AI. Last updated on 12 Jun 2026.

AstraZeneca News

AllArticlesVideos

The Healthcare M&A Wave

Forbes·1 day ago

Ozempic Linked To Lower Risk Of Violence In New Study

Forbes·1 day ago

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

Business Wire·6 days ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.